GeneFab Showcases Breakthrough Strategies in CAR-NK Cell Expansion and Scalable Manufacturing

ALAMEDA, Calif. — November 14, 2025. GeneFab today published new work in BioProcess International demonstrating a process-intensification approach for CAR-NK cell expansion — combining PBS Vertical Wheel bioreactors with XCell ATF perfusion to enable scalable, allogeneic manufacturing of NK cell therapies.

The challenge with NK cell scale-up

Allogeneic CAR-NK therapies have emerged as one of the most promising off-the-shelf cell therapy modalities. They offer a path to broader patient access, lower cost of goods, and faster delivery to clinic than autologous approaches. But scaling NK cell manufacturing is hard — NK cells are notoriously shear-sensitive, demand precise growth conditions, and degrade rapidly when stressed.

Traditional stirred-tank bioreactors generate the kind of localized shear that NK cells don't tolerate well. Static or rocking systems are gentler but cap out at volumes that don't support commercial-scale dosing. Closing that gap — gentle enough for NK biology, scalable enough for commercial supply — has been one of the field's most stubborn engineering problems.

Process intensification — two technologies, one platform

GeneFab's approach combines two complementary technologies:

PBS Vertical Wheel bioreactors use a single, large vertical impeller that delivers uniform mixing across the entire culture volume. The geometry produces low shear, homogeneous nutrient and gas distribution, and — critically — the same hydrodynamic profile from bench scale (0.1 L) all the way to production scale (80 L). That means a process developed at small scale translates directly to manufacturing, without re-optimization.

XCell ATF (Alternating Tangential Flow) perfusion continuously removes spent media and metabolic waste while retaining cells inside the bioreactor — letting cell density climb far beyond what batch or fed-batch operations allow. Combined with the Vertical Wheel's gentle mixing, perfusion creates an environment where NK cells can grow to high densities without the stress that would normally compromise their cytotoxic phenotype.

What the work demonstrates

The case study presented in BioProcess International documents NK cell expansion under intensified conditions — tracking cell density, viability, phenotype (CD56+ purity, activation markers), and cytotoxic function across the campaign. Cells maintain their characteristic NK biology while achieving substantially higher densities per liter than conventional approaches, translating to more doses per batch and better unit economics.

For developers of CAR-NK therapies, this is an immediately useful template: a manufacturing approach that's been benchmarked at the bench, is ready to scale into GMP, and uses well-characterized, commercially available equipment.

Why it matters

Allogeneic CAR-NK therapies will only reach the patients who need them if the manufacturing economics work. Process intensification — getting more cells out of each liter of bioreactor capacity — is one of the most important levers the field has. GeneFab's work demonstrates that the lever is available now, not in some future generation of equipment, and that it can be deployed into cGMP programs today.